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Incidence and long-term outcome of severe 
asthma–COPD overlap compared to asthma 
and COPD alone: a 35-year prospective study 
of 57,053 middle-aged adults
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Background: Incidence and prognosis for severe asthma–COPD overlap is poorly characterized. 
We investigated incidence and long-term outcome for patients with asthma–COPD overlap 
compared to asthma and COPD alone.
Materials and methods: A total of 57,053 adults (aged 50–64 years) enrolled in the Danish 
Diet, Cancer, and Health cohort (1993–1997) were followed in the National Patients Registry 
for admissions for asthma (DJ45–46) and COPD (DJ40–44) and vital status. Asthma–COPD 
overlap was defined as at least one hospital admission for asthma and one for COPD (different 
time points), and incident asthma–COPD overlap as at least one of the diagnoses occurring 
after enrollment into the Diet, Cancer, and Health cohort.
Results: A total of 1,845 (3.2%) and 4,037 (7.1%) participants had admissions for asthma and 
COPD, respectively, with 662 (1.2%) participants with asthma–COPD overlap. Incidence rate of 
asthma–COPD overlap per 1,000 person-years was higher in women (0.73) than in men (0.54) 
(P,0.02). Mortality rate was higher in asthma–COPD overlap (25.9 per 1,000 person-years) com-
pared with COPD (23.1, P,0.05) and asthma (7.9, P,0.001) alone. Compared to COPD alone, 
mortality was higher in women with asthma–COPD overlap (19.6 and 25.5, respectively; P,0.01), 
and the excess mortality rate for asthma–COPD overlap patients was most prominent for younger 
age groups (12.9 compared to 7.2 and 4.6 for COPD and asthma alone, respectively; P,0.01).
Conclusion: This large population-based study revealed a higher incidence of severe asthma–
COPD overlap in women compared to men, and furthermore that all-cause mortality is higher 
in women and younger subjects with asthma–COPD overlap compared with those with asthma 
or COPD alone.
Keywords: asthma, COPD, asthma–COPD overlap, ACOS, outcome, mortality, incidence
Introduction
The occurrence of concomitant asthma and COPD, in recent years often referred to 
as asthma–COPD overlap syndrome (ACOS), is well recognized. However, despite 
much attention, no general consensus has been reached on defining features, or even 
the term itself, with some studies classifying ACO as a subphenotype of COPD,1,2 
and some as a distinct phenotype by itself.3,4 The overlap between asthma and COPD, 
therefore, remains a controversial issue, possibly primarily because many conflicting 
aspects remain, which makes it difficult to summarize the distinctive features of this 
so-called syndrome.5,6 In line with this, the currently available national guidelines, 
including guidelines from Spain,7 Finland,8 and the Czech Republic,9 have defined 
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ACO on the basis of various combinations of major and minor 
criteria, including positive bronchodilator reversibility test, 
airway hyperresponsiveness, sputum eosinophilia, elevated 
total immunoglobulin E (IgE), atopy, and a clinical history 
of asthma before age 40 years.
Previous studies have revealed wide variations in preva-
lence of ACO of 15%–20%4,10,11 (based on physician diag-
nosis of both asthma and COPD) to 17%–60%12–14 (based 
on chronic airflow limitation in subjects with a diagnosis of 
asthma), clearly indicating the impact of the chosen defini-
tion, which also compromises comparisons between studies. 
In the available (in most cases relatively small) studies, 
patients with features of both asthma and COPD seem to have 
more exacerbations,15 leading to more hospitalizations,3,10,16,17 
and more comorbidity16,18,19 than patients with either disease 
alone, as well as poorer health-related quality of life12 and 
higher medical utilization.19 However, studies based on either 
small subpopulations, likely not to be representative of the 
general population, or on additional diagnostic criteria in a 
selected group of either asthma or COPD patients hamper the 
interpretation of the findings. Large-scale population-based 
studies are thus needed to characterize patterns of morbidity 
and mortality further in patients with overlap between asthma 
and COPD. Additionally, very limited observations are at 
present available regarding mortality in patients with ACO. 
The aim of the present study was to investigate incidence 
and mortality of severe ACO compared to asthma and COPD 
only, based on patterns of hospital admissions in a large 
population-based cohort of middle-aged Danish adults.
Materials and methods
Cohort
In 1993–1997, a total of 160,725 individuals (72,729 women) 
50–64 years of age living in the two largest cities in Denmark 
(Copenhagen and Århus), with no record of cancer in the 
Danish Cancer Registry, were invited to participate in the 
prospective Danish Diet, Cancer, and Health (DCH) study. In 
total, 57,053 individuals (29,875 women [52.4%]) accepted 
the invitation and were enrolled in the study. All participants 
answered a detailed questionnaire on diet, health, education, 
occupation, lifestyle, including smoking, reproductive char-
acteristics, and preexisting disease, including asthma, COPD, 
diabetes, and cardiovascular disease. A detailed description 
of the DCH cohort has been published previously.20,21
Health-outcome definitions
Using the unique identification number assigned to all Danish 
citizens,22 the DCH cohort was linked to the Danish National 
Patient Registry (DNPR)21 to extract hospital contacts from 
1978 until July 1, 2013. The DNPR includes all discharge 
diagnoses from all Danish hospitals since 1978 and from 
outpatient clinics since 1995.23 Admissions in the present 
analyses also included emergency room visits and visits to 
pulmonary outpatient clinics, and if not stated otherwise 
referred to as admissions. COPD and asthma diagnoses were 
classified according to the International Classification of Dis-
eases (ICD) as ICD-10 codes DJ40–44 (and 490.0–492.09, 
according to the ICD-8 until 1994) and ICD-10 codes 
DJ45–46 (and ICD-8 codes 493.00–493.09), respectively, 
for COPD and asthma. To allow for variations in classifica-
tion procedures, patients with a primary diagnosis of DJ960 
(acute respiratory failure) were also included, provided they 
had a secondary diagnosis of asthma or COPD. Contacts 
after baseline (ie, 1993–1997) for asthma and/or COPD were 
classified as incident admissions.
Participants were defined as having asthma if during the 
study period they exclusively had admissions for asthma, 
and likewise for participants classified as having COPD. 
Participants were defined as having ACO if they had at least 
one hospital admission for asthma together with at least one 
admission for COPD (two different time points, regardless 
of which came first). In order to be classified as having 
ACO at baseline, participants were required to have at 
least one admission for asthma and also at least one admis-
sion for COPD before enrollment into the cohort. Incident 
ACO was defined as at least one first admission for either 
asthma or COPD occurring after baseline (1993–1997), 
with date of earliest admission as date of ACO onset, and 
likewise for participants classified as having asthma or 
COPD alone.
statistical methods and ethics
For each person, person-years of follow-up were calculated 
separately for asthma, COPD, and ACO, with follow-up start-
ing at the date of inclusion into the cohort (between 1993 and 
1997) and ending on July 1, 2013, date of death, emigration, or 
at the first admission for asthma, COPD, or ACO, respectively, 
whichever came first. Overall and age-specific incidence rates 
and mortality rates were calculated for asthma, COPD, and 
ACO, and separately for men and women. The ages were 
stratified into four intervals, from age 50 years to age 75+ 
years. Incidence rates were calculated by dividing the number 
of cohort participants with an event (asthma, COPD, or ACO) 
in each age-group by the total person-years of observation 
for all participants in that stratum, overall and separately by 
gender, and reported as incidence rates per 1,000 person-years. 
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Age-specific mortality rates were calculated by dividing the 
number of deaths due to any cause – overall and in each age-
group – by the number of person-years of observations for all 
participants in that stratum. Confidence intervals (95%) were 
calculated for incidence and mortality rates based on Poisson 
distribution, using the “stptime” command in Stata 13.1. The 
DCH-cohort study was approved by the Central Danish Ethics 
Committee, and the present study was approved by the Danish 
Data Protection Agency (2014-41-3468). All participants 
provided written informed consent.
Results
The participants (n=57,053) in the DCH cohort were 
registered with a total of 2,762,912 hospital discharge 
diagnoses in the DNPR between 1978 and 2013, with a total 
of 1,268,971 primary diagnoses. Of these primary diagnoses, 
18,311 (1.4%) were for either asthma (n=3,961 [21.6%]) or 
COPD (n=14,350 [78.4%]) (Figure 1). Furthermore, a total 
of 1,445 admissions were identified with acute respiratory 
failure (DJ960) as the primary diagnosis, 871 of these with 
a secondary diagnosis of asthma (n=16) or COPD (n=855) 
(Figure 1). A total of 3,977 admissions for asthma and 15,205 
admissions for COPD were thus included in the present anal-
yses, with 1,845 participants having at least one admission 
for asthma and 4,037 at least one admission for COPD.
Participants with admissions for asthma 
or COPD
Of 57,053 subjects in the DCH cohort, 1,183 (2.1%) had 
had at least one admission for asthma (and none for COPD) 
between 1978 and 2013, with 368 (31.1%) and 815 (68.9%), 
respectively, before and after baseline (1993–1997), corre-
sponding to an incidence rate of 0.9 per 1,000 person-years, 
with a higher asthma-incidence rate for women (1.07 per 
1,000 person-years) than men (0.72 per 1,000 person-years) 
(P,0.02; Table 1). A total of 3,375 (5.9%) cohort partici-
pants had had at least one admission for COPD (and none for 
asthma), with 361 (10.7%) and 3,014 (89.3%), respectively, 
before and after baseline, and thus an incidence rate of 3.4 per 
1,000 person-years. Incidence rates for COPD were similar 
for men (3.3 per 1,000 person-years) and women (3.4 per 
1,000 person-years) (Table 1). Only a minor portion of the 
included admissions for asthma or COPD (14.2% and 12.7%, 
respectively) were emergency room visits.
Participants with aCO
A total of 662 participants (1.2% of the cohort) had had at 
least one admission for both asthma and COPD, ie, fulfilled 
the criteria for ACO. The subjects enrolled in the cohort with 
at least one admission for obstructive lung disease could 
thus be grouped into: asthma only (n=1,183), COPD only 
Figure 1 Flowchart describing participants included in the present study from the Diet, Cancer, and health cohort.
Notes: Based on discharge diagnoses of asthma and/or COPD, either as a primary diagnosis or as a secondary diagnosis to acute respiratory failure (1978–2013). Data from 
the Diet, Cancer, and health cohort: Tjønneland et al20 and Bonnelykke et al.21
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(n=3,373), and ACO (n=662). Therefore, 35.9% (662 of 
1,845) of participants with at least one admission for asthma 
and 16.4% (662 of 4,037) of participants with at least one 
admission for COPD were classified as having ACO. At base-
line, 74 participants had ACO (11.2% of all ACO), with no 
difference between men and women (5.6% each of all ACO). 
Overall incidence of ACO was 0.64 per 1,000 person-years, 
women having a higher incidence than men (0.73 vs 0.54 per 
1,000 person-years; P,0.02) (Table 1, Figure 2).
Mortality
The overall mortality rate (all subjects enrolled in the cohort) 
was 10.9 per 1,000 person-years, with men having a 63% 
higher mortality rate than women (13.7 vs 8.4 per 1,000 
person-years) (Table 2). This gender difference in mortal-
ity was less pronounced in the ACO group, with only 4.3% 
higher mortality in men (not significant).
Total mortality (all participants in the three groups of 
interest) was higher among participants with ACO (25.9 per 
1,000 person-years) than among those with asthma alone or 
COPD alone (7.9 [P,0.001] and 23.1 [P,0.01] per 1,000 
person-years, respectively) (Table 2, Figure 3). The differ-
ence in mortality between the three groups of subjects with 
obstructive lung disease was observed especially in women 
(25.5, 6.9 [P,0.001], and 19.6 [P,0.01] per 1,000 person-
years, for ACO, asthma, and COPD, respectively) and in 
younger participants (total mortality 12.9, 4.6 [P,0.01], and 
7.2 [P,0.01], respectively, in the age-group 55–65 years). 
After age 75 years, mortality was higher for COPD than for 
ACO (75.5 vs 57.2 per 1,000 person-years, respectively).
In subjects below age 55 years, no deaths were observed 
in the asthma-only group, whereas the mortality rate for ACO 
Figure 2 Incident cases of COPD, asthma, and asthma–COPD overlap.
Note: Participants with first-ever hospital admission for asthma, COPD, or both, ie, 
asthma–COPD overlap, after baseline (1993–1997) per 1,000 person-years overall 
and according to gender.
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(4.4 per 1,000 person-years) was higher than for COPD only 
(2.8 per 1,000 person-years), although the number of events 
was limited (Table 2). At age 55–65 years, mortality was 
significantly higher among men in the ACO group compared 
to women (14.5 vs 11.9 per 1,000 person-years, respectively; 
P,0.05). This reversed with age, as no significant differences 
were found in mortality between men and women in the ACO 
group after age 65 years (Table 2).
Discussion
The major new findings of this prospective study of a large 
middle-aged population-based cohort are that incident severe 
ACO (also referred to as ACOS) is more common among 
females than males, and that patients with ACO have higher 
mortality rates compared to both asthma alone and COPD 
alone, especially among women and younger age-groups. 
Our study, therefore, emphasizes that individuals, and not 
least women, with ACO of such severity that it causes 
hospital admissions constitute a high-risk group for very 
poor outcome.
Incidence of aCO
Although we only studied individuals with ACO leading to 
hospital contacts, together with the fact that comparison with 
previous studies was hampered by the different definitions 
of ACO used, we observed a prevalence of ACO similar to 
several previous studies, including Sorino et al,24 Menezes 
et al,3 and Miravitlles et al.17 In contrast to our findings, 
Diaz-Guzman et al25 reported an overall prevalence of 
ACOS of 2.7%, corresponding to a prevalence of 43.8% 
among their COPD patients, based on self-reported asthma 
and COPD, very similar to a previous study by Lange et al.15 
These differences might be due to the use of self-reported 
asthma as part of the ACOS definition, as participants 
might report COPD as asthma, and probably also differ-
ences in the age span of individuals studied.11,26,27 Our use 
of registry records (with discharge diagnoses) eliminated 
the risk of faulty reporting by participants, but of course 
did not eliminate the risk of doctor misclassification. The 
discrepancy in incidence and prevalence of ACO observed 
in different studies implies an intrinsic weakness in defin-
ing this “phenotype” of obstructive lung disease,28–30 and 
the future use of this umbrella term can be questioned, not 
only because it blurs the lines between asthma and COPD 
but also because it may allow an approach that simplifies 
therapy.6 This assumption may seem to be supported not 
only by recently published clinical treatment guidelines, 
which by definition are not based on evidence from ran-
domized clinical trials, as individuals with ACO have not 
been eligible for inclusion,31 but also recently published 
reviews.29,32 Future studies should thus (by adding to existing 
knowledge, including the present study) seek to define new 
phenotypes and underlying endotypes of obstructive lung 
disease with characteristics of both asthma and COPD to 
replace the umbrella term “ACO”.
Our study revealed a higher incidence of ACO in women 
compared to men, which is in line with a previous study 
by Diaz-Guzman et al,25 but in contrast to the study by 
Lange et al,15 based on the Danish Copenhagen City Heart 
study. Incident hospital admissions for asthma are common in 
postmenopausal women,21 and we are thus confident that our 
observation was not caused by gender-related misclassifica-
tion of obstructive lung diseases, but instead represents male–
female difference in susceptibility to develop an overlapping 
phenotype, revealed in the present study by a combination 
of cohort size and disease severity studied.
Mortality
With regard to mortality in individuals with ACO, so far only 
limited evidence is available. Similar to our results, Diaz-
Guzman et al25 found overlap patients to have a hazard ratio 
for mortality of 1.83 compared to subjects without obstruc-
tive lung disease. This compared with hazard ratios of 1.44 
for COPD-only and 1.16 for asthma-only participants, the 
hazard ratio reported for COPD only being very similar to that 
reported by Lange et al15 for ACO with late-onset asthma. In 
contrast, Yamauchi et al33 found lower in-hospital, all-cause 
mortality in overlap patients than in COPD-only patients 
(2.3% vs 9.7%, respectively), based on physician diagnoses 
of both asthma and COPD. Furthermore, a recent study by 
Sorino et al,24 investigating 15-year mortality rates in 1,065 
subjects aged .65 years, reported no difference in mortality 
Figure 3 all-cause mortality rates per 1,000 person-years.
Note: rates overall and according to gender in the entire cohort (n=57,053) and for 
participants with COPD (n=3,375), asthma (n=1,183), and asthma–COPD overlap 
(n=662).
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between ACO and COPD only. In line with that, based on 
data from a large COPD cohort, Cosio et al34 identified 
patients with one major or two minor criteria for asthma, and 
reported a lower 1-year mortality for patients in the overlap 
group than COPD only (cumulative survival of 94.7% and 
87.3%, respectively). This is again in accordance with a study 
by Fu et al,35 who studied prognoses in 99 adults with asthma, 
COPD, and ACO after a median follow-up of 4.2 years, 
where patients with COPD were found to have poorer prog-
noses than the two other groups. Possible explanations for 
the differences in findings, apart from the difficulties with 
diagnostic labeling already discussed, may be the size of 
the cohort and overall severity of obstructive lung disease 
in the studied cohort, as in the present study, where we only 
included individuals in the three groups of interest, provided 
the disease had caused admission to hospital. Our study of a 
very large population-based cohort focusing on individuals 
with obstructive lung diseases at the more severe end of the 
disease spectrum has shown that individuals with overlap 
between asthma and COPD have a poorer prognosis than 
individuals with either disease alone. Although, in relation 
to the latter, one limitation of the present study is the lack 
of information on cause-specific mortality.
Overall, we feel confident that our data are a sound 
representation of the actual hospital contacts for asthma 
and COPD, as we relied on physicians having seen and 
diagnosed the patients in a hospital setting with access to a 
full overview of each patient’s symptoms, clinical findings, 
and paraclinical results, including spirometry and imaging, 
and not relying on either alone.
study limitations
The diagnoses in this study were physician-based assess-
ments, from a registry, and might not have been confirmed 
by a specialist in respiratory medicine, although the diagnosis 
is highly likely to have been confirmed by objective assess-
ment for patients attending a respiratory outpatient clinic. 
Data from registers might be vulnerable to errors, due to 
lack of time or clinical experience or to change in diagnostic 
practices over time, although diagnostic practices have 
been relatively stable over the years of the present study, 
including awareness of the differential diagnosis of asthma 
and COPD.36 Furthermore, Thomsen et al37 reported a 92% 
positive predictive value (PPV) for a discharge diagnosis of 
COPD in the DNPR, the same register as that used in the 
present study, and with respect to this, the diagnoses in the 
register are highly likely to be reliable. With regard to asthma, 
Jensen et al38 found sensitivity of a DNPR record of asthma to 
be 44%, but specificity to be 98%, with a positive predictive 
value of 65%. However, they found that the low sensitivity 
for asthma did not nullify any observed relative associations 
in the data set. In addition, we did not have available data 
on disease severity, eg, for patients with COPD according to 
the Global Initiative for Chronic Obstructive Lung Disease 
strategy document, but our classification criteria of hospital 
admission were highly likely to have excluded most patients 
with milder disease. On the other hand, although hospital 
admissions for obstructive lung disease represent the more 
severe end of the disease spectrum, the burden most likely 
reflects the total disease burden. Another limitation related 
to the use of a population-based cohort, and by that a more 
descriptive approach, was the lack of data for important 
clinical features, including level of lung function, degree of 
airflow limitation, type of airway inflammation, and disease-
related physical limitations, all information that would have 
been useful to classify our patients further.
In conclusion, the present study of a large population-
based cohort highlights differences in the long-term outcome 
of patients with more severe ACO compared to asthma and 
COPD alone. In particular, our study revealed important 
gender differences in incidence and long-term outcome of 
ACO, including a lower survival rate in individuals with 
ACO compared to both asthma and COPD only. Our find-
ings, therefore, support the notion that patients presenting 
features of both asthma and COPD are at high risk of a poor 
long-term outcome.
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